Ophiocordyceps sinensis in Cancer Therapy: Bridging Traditional Medicine and Modern Oncology

Ophiocordyceps sinensis, a parasitic fungus traditionally used in Asian medicine, has drawn attention for its potential anticancer properties. Its bioactive components- such as cordycepin, polysaccharides, and nucleosides-exhibit anti-inflammatory, antioxidant, immunomodulatory, and anticancer activities.

This study reviews preclinical evidence from in vitro and in vivo models evaluating the anticancer effects of O. sinensis against various cancers, including lung, breast, liver, and colon. Mechanistic assessments focused on apoptosis induction, cell cycle regulation, angiogenesis inhibition, and immune modulation.

Cordycepin, a key active compound, was found to induce apoptosis via caspase activation and Bcl-2 family protein modulation. Additionally, O. sinensis inhibited angiogenesis, disrupted cancer cell proliferation through cell cycle arrest, and reduced oxidative stress. Its immunomodulatory effects were also noted to enhance anti-tumor immune responses. Some studies suggest it may potentiate traditional cancer therapies by mitigating treatment-induced immunosuppression and tissue damage.

These preclinical findings highlight O. sinensis as a promising natural anticancer agent. Its multifaceted mechanisms align with modern therapeutic goals such as immune engagement and tumor microenvironment modulation. However, current evidence is limited to preclinical settings. Variability in bioactive compound content and concerns about bioavailability remain major challenges.

Ophiocordyceps sinensis demonstrates encouraging anticancer potential in preclinical models. Further clinical studies are essential to validate its efficacy, establish safety profiles, and optimize formulation for therapeutic use.